The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
How Large Will The Somatostatin Analogs Market Be By 2030 Compared To Its 2026 Market Size?
The somatostatin analogs market has demonstrated significant expansion in recent years. The market is projected to expand from $7.16 billion in 2025 to $7.66 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.1%. Historically, this expansion was fueled by an increase in neuroendocrine tumor diagnoses, the widespread occurrence of hormone disorders, compelling clinical efficacy evidence, the influence of specialist prescribing, and greater hospital accessibility.
The somatostatin analogs market is projected to experience robust expansion in the coming years. Its value is forecast to reach $10.15 billion by 2030, expanding at a compound annual growth rate (CAGR) of 7.3%. Key drivers for this growth during the forecast period include the introduction of biosimilars, broader therapeutic applications, the increasing elderly population, enhanced diagnostic accuracy, and favorable reimbursement policies for specialty drugs. Significant trends anticipated in the forecast period encompass the rise of long-acting injectable formulations, new indications for neuroendocrine tumors, a heightened focus on patient adherence, ongoing biosimilar development, and an increase in hospital-administered therapies.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10840&type=smp
What Key Drivers Are Fueling The Growth Of The Somatostatin Analogs Market?
The increasing demographic of older individuals is anticipated to fuel the expansion of the somatostatin analogs market in the future. An aging population signifies a demographic change marked by an elevated proportion or a rising count of people within a society who are 65 years old or more. This surge in the elderly demographic is linked to a greater occurrence of illnesses requiring Somatostatin Analogs, thereby boosting the demand for these drugs. For example, data from the UK Parliament’s House of Commons Library, a government body based in the UK, indicated that in July 2024, there were 12.7 million individuals aged 65 or above in the UK in 2022, constituting 19% of the overall population. This figure is projected to climb to 22.1 million by 2072, making up 27% of the population. Consequently, the expanding aging population is serving as a key impetus for the somatostatin analogs market’s growth.
How Are Different Segments Classified In The Somatostatin Analogs Market Segment Analysis?
The somatostatin analogs market covered in this report is segmented –
1) By Type: Octreotide, Lanreotide, Pasireotide
2) By Treatment: Acromegaly, Cushing’s Syndrome, Neuroendocrine Tumors, Carcinoid Syndrome, Other Treatments
3) By End User: Hospital, Pharmaceutical Companies
Subsegments:
1) By Octreotide: Long-Acting Release (LAR) Formulations, Short-Acting Formulations
2) By Lanreotide: Depot Formulations, Injectable Formulations
3) By Pasireotide: Long-Acting Injectable Formulations, Subcutaneous Formulations
What Trends Are Influencing The Somatostatin Analogs Market?
Major companies operating in the somatostatin analogs market are prioritizing the development of advanced products, such as targeted radiopharmaceuticals, to improve the accuracy and effectiveness of cancer treatments, especially for patients with somatostatin receptor-positive tumors. Targeted radiopharmaceuticals are specialized medications that integrate radiation-emitting isotopes with molecules designed to selectively attach to cancer cells, facilitating the precise delivery of therapeutic radiation to tumor sites while minimizing harm to surrounding healthy tissues. For instance, in January 2024, Lantheus, a US-based company focused on radiopharmaceuticals, introduced Lutetium Lu 177 Dotatate. Lutetium Lu-177 Dotatate is a radiolabeled somatostatin analog utilized in peptide receptor radionuclide therapy (PRRT) for treating advanced somatostatin receptor-positive neuroendocrine tumors. Clinical research has shown that it considerably enhances progression-free survival and response rates compared to older somatostatin analogs like octreotide, positioning it as an essential alternative for patients whose disease has advanced despite prior therapies. Its focused strategy enables effective tumor management while reducing systemic exposure, thereby elevating the overall therapeutic outcome in addressing neuroendocrine malignancies.
Who Are The Companies Driving Activity In The Somatostatin Analogs Market?
Major companies operating in the somatostatin analogs market are Novartis International AG, Pfizer Inc., Sun Pharmaceutical Industries Limited, Midatech Pharma plc, Crinetics Pharmaceuticals Inc., Peptron Inc., Teva Pharmaceutical Industries Ltd., Camurus AB, Bayer Aktiengesellschaft, Cadila Healthcare Limited, Amneal Pharmaceuticals Inc., Recordati S.p.A., Amryt Pharma plc, Ipsen Pharma SA, Fresenius Kabi AG, Chiasma Inc., Merck KGaA, Sanofi S.A., Sandoz International GmbH, Takeda Pharmaceutical Company Limited, Viatris Inc., AstraZeneca plc, Johnson & Johnson, Genentech Inc., OctreoPharm Sciences GmbH
Get The Full Somatostatin Analogs Market Report:
https://www.thebusinessresearchcompany.com/report/somatostatin-analogs-global-market-report
Where Is The Somatostatin Analogs Market Most Concentrated Geographically?
North America was the largest region in the global somatostatin analogs treatment market in 2025.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the somatostatin analogs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Somatostatin Analogs Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/somatostatin-analogs-global-market-report
Browse Through More Reports Similar to the Global Somatostatin Analogs Market 2026, By The Business Research Company
Sorbitol Market Report 2026
https://www.thebusinessresearchcompany.com/report/sorbitol-global-market-report
Aspirin Market Report
https://www.thebusinessresearchcompany.com/report/aspirin-global-market-report
Sorbates Market Report
https://www.thebusinessresearchcompany.com/report/sorbates-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model